Clinical Trial

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

Study acronym: SpA23
Recruiting
View on ClinicalTrials.gov →
Summary
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-11; most recent amendment 2025-01-21.
Status change: Not Yet Recruiting → Recruiting 2023-03-09
Trial Details
NCT Number NCT05290363
Lead Sponsor Institut Pasteur
Collaborators: Janssen Biotech, Inc.
Conditions Spondyloarthritis
Enrollment 90 participants
Start Date 2022-10-06
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-23